Watson Challenges Cancer

The IBM supercomputer, famous for its game show performance, will aid in cloud-based analyses of genomic data.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, CLOCKREADYIBM’s Watson, a supercomputer and one of the most famous “Jeopardy!” champions, will now be deployed in the service of oncologists. The New York Genome Center and IBM this week (March 19) announced a partnership through which Watson will analyze genomic data, with the goal of developing personalized medicine for cancer patients.

“We’re hoping Watson’s learning model can find associations faster than we can and they’ll be able to tune the sets of drugs to at least prioritize and give doctors the ability to drill down so that they can make better determinations of what to try,” Toby Bloom, the deputy scientific director for informatics at the New York Genome Center, told Forbes.

At the outset, Watson will compare genomic data from tumors and non-tumorous tissue from a small group of patients with glioblastoma, a notoriously difficult-to-treat brain cancer. “Time definitely is not on your side when you have glioblastoma and that’s where Watson comes in,” Robert Darnell, the New York Genome Center’s president, CEO, and scientific director, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies